Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis.

Zhu Q, Tong Y, Wu T, Li J, Tong N.

Clin Ther. 2013 Jun;35(6):880-99. doi: 10.1016/j.clinthera.2013.03.020. Epub 2013 Apr 18.

PMID:
23602502
2.

No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.

Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH.

Diabetes Care. 1998 Oct;21(10):1612-8.

PMID:
9773719
3.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
4.
5.

Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis.

Li Y, Tong Y, Zhang Y, Huang L, Wu T, Tong N.

Int J Clin Pract. 2014 Nov;68(11):1318-32. doi: 10.1111/ijcp.12467. Epub 2014 May 23. Review.

PMID:
24853116
6.
7.

Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis.

Gu S, Shi J, Tang Z, Sawhney M, Hu H, Shi L, Fonseca V, Dong H.

PLoS One. 2015 May 11;10(5):e0126704. doi: 10.1371/journal.pone.0126704. eCollection 2015. Review.

9.

Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.

Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, bin Abdul Kadir DK, Cho CG, Sridama W; Writing Group for the Asian Study of Acarbose with Sulfonylureas.

J Diabetes Complications. 2003 Jul-Aug;17(4):179-85. Erratum in: J Diabetes Complications. 2005 Jul-Aug;19(4):following 246. Huarng, Jyuhn [corrected to Juang, Jyuhn-Huarng].

PMID:
12810240
10.
11.

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J.

Diabetes Care. 1998 Dec;21(12):2050-5.

PMID:
9839093
12.

Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.

Salman S, Salman F, Satman I, Yilmaz Y, Ozer E, Sengül A, Demirel HO, Karşidağ K, Dinççağ N, Yilmaz MT.

Curr Med Res Opin. 2001;16(4):296-306.

PMID:
11268714
13.

[A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].

Pan CY, Gao Y, Li GW, Zhu XX, Gao X, Liu X.

Zhonghua Nei Ke Za Zhi. 2009 Apr;48(4):304-7. Chinese.

PMID:
19576120
14.

Acarbose Monotherapy and Type 2 Diabetes Prevention in Eastern and Western Prediabetes: An Ethnicity-specific Meta-analysis.

Hu R, Li Y, Lv Q, Wu T, Tong N.

Clin Ther. 2015 Aug;37(8):1798-812. doi: 10.1016/j.clinthera.2015.05.504. Epub 2015 Jun 26. Review.

PMID:
26118669
15.

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.

Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, Ragghianti B, Monami F, Marchionni N, Mannucci E.

Adv Ther. 2012 Sep;29(9):736-46. doi: 10.1007/s12325-012-0045-5. Epub 2012 Aug 24. Review.

PMID:
22923161
16.

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.

Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB.

Diabetes Care. 1995 Jun;18(6):817-24.

PMID:
7555508
17.

Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study.

Hasche H, Mertes G, Bruns C, Englert R, Genthner P, Heim D, Heyen P, Mahla G, Schmidt C, Schulze-Schleppinghof B, Steger-Johannsen G.

Diabetes Nutr Metab. 1999 Aug;12(4):277-85.

PMID:
10782754
18.

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM.

Ann Intern Med. 1994 Dec 15;121(12):928-35.

PMID:
7734015
19.

Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes.

Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP.

Clin Exp Pharmacol Physiol. 2010 May;37(5-6):564-8. doi: 10.1111/j.1440-1681.2010.05361.x. Epub 2010 Jan 17.

PMID:
20082624
20.

Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review.

Derosa G, Maffioli P.

Clin Ther. 2012 Jun;34(6):1221-36. doi: 10.1016/j.clinthera.2012.04.012. Epub 2012 May 5. Review.

PMID:
22560622

Supplemental Content

Support Center